UCB selects ZoBio for Fragment Based Drug Discovery services
ZoBio BV announced that UCB S.A. has selected ZoBio to provide ligand discovery services in the field of Fragment Based Drug Discovery. The agreement provides for initial ligand screening of UCB discovery targets. ZoBio will immobilize the targets and carry out ligand screening using its proprietary Target Immobilized NMR Screening (TINS) technology.
"UCB is always searching for innovative solutions to overcome the challenges in drug discovery", said Mark Bushfield, Vice President, NCE Research. "We feel that TINS is a robust platform that can help generate novel lead series for our targets and give us a competitive advantage."
"ZoBio is proud to be recognized by UCB as a valuable and reliable partner in drug discovery", said Gregg Siegal, Chief Scientific Officer of ZoBio. "TINS has been validated on targets from multiple customers and we are confident that it will provide novel ligands for even the most challenging of UCB's targets".
Other news from the department business & finance
